
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is expected to continue to see growth in all four of its business units, with strong performance and a focus on shareholder returns through dividends and share repurchases. The company also has a strong pipeline for potential acquisitions and has announced key product launches for the fiscal year. While the separation of its Lifesciences business may drive future growth, challenges in certain segments and regions may impact its performance in the near term. Overall, Becton Dickinson has strong financials and a positive outlook, with a potential stock value ranging from $140 to $185.
Bears say
Becton Dickinson is expected to generate average HSD EPS growth through the projected period of FY2030, aided by their BD Excellence initiative to drive margin expansion and accelerate revenue growth. However, there are several risks that may impact the company's growth, including potential challenges with the separation of its Biosciences and Diagnostics divisions and ongoing headwinds in the industry such as funding cuts and changing healthcare delivery and reimbursement practices. Furthermore, competition in all segments and global economic conditions may also create headwinds for the company's operations.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares